GRAIL, Inc. (NASDAQ:GRAL) shares plummeted 16.15% during Monday's pre-market session.
The sharp decline follows the release of results from the NHS-Galleri trial, which evaluated the effectiveness of GRAIL's Galleri test in reducing late-stage cancer diagnoses. While the trial showed a favorable trend in reducing Stage IV cancer diagnoses, the primary endpoint was not met.
The stock had already closed nearly 51% lower on the previous trading day, indicating continued negative investor sentiment following the trial results announcement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments